JPWO2019246176A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019246176A5 JPWO2019246176A5 JP2020570743A JP2020570743A JPWO2019246176A5 JP WO2019246176 A5 JPWO2019246176 A5 JP WO2019246176A5 JP 2020570743 A JP2020570743 A JP 2020570743A JP 2020570743 A JP2020570743 A JP 2020570743A JP WO2019246176 A5 JPWO2019246176 A5 JP WO2019246176A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- group
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 56
- 102000036639 antigens Human genes 0.000 claims description 56
- 108091007433 antigens Proteins 0.000 claims description 56
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 108010080865 Factor XII Proteins 0.000 claims description 15
- 102000000429 Factor XII Human genes 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 8
- 108090000190 Thrombin Proteins 0.000 claims description 6
- 206010047249 Venous thrombosis Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960004072 thrombin Drugs 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 201000007272 intracranial sinus thrombosis Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108010071241 Factor XIIa Proteins 0.000 claims description 3
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 206010014522 Embolism venous Diseases 0.000 claims description 2
- 206010019636 Hepatic artery thrombosis Diseases 0.000 claims description 2
- 206010023237 Jugular vein thrombosis Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 201000009454 Portal vein thrombosis Diseases 0.000 claims description 2
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims description 2
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000006624 extrinsic pathway Effects 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000004043 venous thromboembolism Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024099610A JP2024116399A (ja) | 2018-06-19 | 2024-06-20 | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687144P | 2018-06-19 | 2018-06-19 | |
| US62/687,144 | 2018-06-19 | ||
| PCT/US2019/037865 WO2019246176A1 (en) | 2018-06-19 | 2019-06-19 | Anti-factor xii/xiia antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024099610A Division JP2024116399A (ja) | 2018-06-19 | 2024-06-20 | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527424A JP2021527424A (ja) | 2021-10-14 |
| JPWO2019246176A5 true JPWO2019246176A5 (https=) | 2022-06-20 |
| JP2021527424A5 JP2021527424A5 (https=) | 2022-06-20 |
| JP7634993B2 JP7634993B2 (ja) | 2025-02-25 |
Family
ID=67263076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570743A Active JP7634993B2 (ja) | 2018-06-19 | 2019-06-19 | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
| JP2024099610A Pending JP2024116399A (ja) | 2018-06-19 | 2024-06-20 | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024099610A Pending JP2024116399A (ja) | 2018-06-19 | 2024-06-20 | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12068729B2 (https=) |
| EP (1) | EP3810270A1 (https=) |
| JP (2) | JP7634993B2 (https=) |
| KR (1) | KR20210022650A (https=) |
| CN (1) | CN112437682B (https=) |
| AU (1) | AU2019288299B2 (https=) |
| CA (1) | CA3104470A1 (https=) |
| EA (1) | EA202190056A1 (https=) |
| IL (1) | IL279529A (https=) |
| MA (1) | MA52966A (https=) |
| MX (1) | MX2020013894A (https=) |
| WO (1) | WO2019246176A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240352150A2 (en) * | 2020-06-16 | 2024-10-24 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
| JP2023531315A (ja) * | 2020-07-03 | 2023-07-21 | シーエスエル・イノベーション・プロプライエタリー・リミテッド | 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤 |
| EP4729546A1 (en) * | 2023-06-16 | 2026-04-22 | Jiangsu BioJeTay Biotechnology Co., Ltd. | Antibody specifically recognizing factor xiia and use thereof |
| IL325613A (en) * | 2023-07-19 | 2026-02-01 | Regeneron Pharma | Antibodies against factor xii/xiia and their uses |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6891394B1 (en) * | 2002-06-04 | 2005-05-10 | Actel Corporation | Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers |
| US7378867B1 (en) * | 2002-06-04 | 2008-05-27 | Actel Corporation | Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CA2591786C (en) | 2004-12-23 | 2013-07-16 | Bernhard Nieswandt | Prevention of thrombus formation and/or stabilization |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US7541838B2 (en) * | 2007-03-27 | 2009-06-02 | Intel Corporation | Transmitter swing control circuit and method |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
| EP2384766A1 (en) * | 2010-05-03 | 2011-11-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel antibody to a carbonic anhydrase |
| CN103415301A (zh) | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| BR112014001255B1 (pt) | 2011-07-19 | 2019-07-02 | Merck Sharp & Dohme B.V. | Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto |
| ES3005912T3 (en) * | 2011-07-22 | 2025-03-17 | Csl Behring Gmbh | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| KR101461652B1 (ko) * | 2011-12-16 | 2014-11-21 | 주식회사 삼양바이오팜 | 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법 |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| TWI613215B (zh) * | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| WO2014089493A1 (en) * | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| KR20150139089A (ko) * | 2014-06-02 | 2015-12-11 | 한국전자통신연구원 | 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로 |
| US10259874B2 (en) * | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| CN111919424A (zh) * | 2018-07-02 | 2020-11-10 | 拉姆伯斯公司 | 利用早期高阶符号检测用于判决反馈均衡的方法和电路 |
-
2019
- 2019-06-19 MA MA052966A patent/MA52966A/fr unknown
- 2019-06-19 CN CN201980046743.3A patent/CN112437682B/zh active Active
- 2019-06-19 WO PCT/US2019/037865 patent/WO2019246176A1/en not_active Ceased
- 2019-06-19 JP JP2020570743A patent/JP7634993B2/ja active Active
- 2019-06-19 MX MX2020013894A patent/MX2020013894A/es unknown
- 2019-06-19 US US17/253,279 patent/US12068729B2/en active Active
- 2019-06-19 EA EA202190056A patent/EA202190056A1/ru unknown
- 2019-06-19 KR KR1020217001188A patent/KR20210022650A/ko not_active Ceased
- 2019-06-19 AU AU2019288299A patent/AU2019288299B2/en active Active
- 2019-06-19 EP EP19739793.8A patent/EP3810270A1/en active Pending
- 2019-06-19 CA CA3104470A patent/CA3104470A1/en active Pending
-
2020
- 2020-12-17 IL IL279529A patent/IL279529A/en unknown
-
2024
- 2024-06-20 JP JP2024099610A patent/JP2024116399A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7366988B2 (ja) | 抗凝固因子ｘｉ抗体 | |
| JP2021527424A5 (https=) | ||
| US9125895B2 (en) | Anti-factor XI monoclonal antibodies and methods of use thereof | |
| JP7271430B2 (ja) | 抗ｘｉ因子抗体 | |
| AU2017236063B2 (en) | Monoclonal antibodies against the active site of factor XI and uses thereof | |
| CA2916399C (en) | Combination therapy using a factor xii inhibitor and a c1-inhibitor | |
| CN114478782B (zh) | 抗凝血因子xi抗体 | |
| WO2010045518A1 (en) | Compositions containing thrombomodulin domains and uses thereof | |
| CN117487016A (zh) | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 | |
| JPWO2019246176A5 (https=) | ||
| US11958911B2 (en) | Anti-coagulation factor XI antibody | |
| JP2009503009A (ja) | 抗血小板剤としての直接的および間接的エフェクター細胞プロテアーゼ受容体−１（ｅｐｒ−１）阻害剤 | |
| JP2007508352A5 (https=) | ||
| HK40075244A (en) | Anticoagulant factor xi antibodies | |
| HK40075243A (en) | Anticoagulant factor xi antibodies | |
| JPWO2022159875A5 (https=) | ||
| TW202546001A (zh) | 用於治療凝血病變的方法 | |
| HK40057273A (en) | Anti-factor xi antibodies | |
| HK40075244B (zh) | 抗凝血因子xi抗体 | |
| NZ756365B2 (en) | Tissue factor pathway inhibitor antibodies and uses thereof | |
| HK40057273B (zh) | 抗凝血因子xi抗体 | |
| HK40010556A (en) | Anti-coagulation factor xi antibody | |
| JPWO2022223966A5 (https=) | ||
| JPWO2020251924A5 (https=) | ||
| JPWO2023070097A5 (https=) |